Reimbursement Scheme Isturisa®
The health insurer does not fully reimburse Isturisa® 1mg, 5mg and 10mg. The producer of this medicine has therefore asked TBR...
Termination TerugBetaalRegeling Forxiga® - Chronic Kidney Disease
From May 1st 2022 onwards, Forxiga® (dapagliflozine) 10 mg for the treatment of chronic kidney disease (CKD) is fully reimbursed...
Extension to TerugBetaalRegeling Elvanse®
The health insurer does not fully reimburse Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. The manufacturer of this...
Reimbursement Scheme Ontozry® (12.5mg/25mg, 50 mg, 100 mg, 150mg)
The health insurer does not fully reimburse ONTOZRY® (12.5mg/25mg, 50 mg, 100 mg, 150mg). The producer of this medicine has...
Reimbursement Scheme Jardiance® (empagliflozin)10 mg for patients with HFpEF (Ejection fraction>40%)
The health insurer does not yet fully reimburse Jardiance (Empagliflozin)® 10 mg for the treatment of HFpEF (Ejection fraction...
Select your medicine
Check your medicine expenses
Quickly check the maximum contribution you have to pay for your medicine